



P&T Committee Meeting

Wednesday, April 10, 2013

Lazarus Building, room C621 *

50 W. Town St., Columbus, OH 43215

10:00 AM

- 1) Interested party presentations **
- 2) New PDL Drugs
 - a) Anti-Rheumatic Drugs: Xeljanz (tofacitinib citrate) tablets, Pfizer
 - b) Blood Agents, Oral Anticoagulants: Eliquis (apixiban) tablets, BMS/Pfizer
 - c) CNS, ADHD Agents: Quillivant XR (methylphenidate) extended-release oral suspension CII, Pfizer
 - d) Endocrine, Diabetes – Oral Hypoglycemics: Invokana (canagliflozin) tablets, Janssen
 - e) Respiratory, COPD: Combivent Respimat (ipratropium bromide and albuterol) inhalation spray, Boehringer Ingelheim
 - f) Topical, Anti-Parasitics: Sklice (ivermectin) lotion, Sanofi Pasteur
- 3) PDL information for June 12 meeting
 - a) New drug classes
 - i) Cardiovascular, Antianginal Agents
 - ii) CNS, Anticonvulsants
 - iii) Infectious Disease, Antivirals for HIV
 - iv) Respiratory, Self-Injected Epinephrine
 - v) Topical, Androgenic Agents
 - b) Review of current drug classes with remaining questions from the committee
- 4) Atypical antipsychotic use in children and nursing facility residents

* Lazarus Building Security requires that visitors show a photo ID, be signed in by staff, wear a visitor badge and be escorted while in the building. Bags may be searched. Please arrive early for security procedures to be completed

** Any interested party may request to present information to the P&T Committee. Guidelines are posted at <http://jfs.ohio.gov/ohp/bhpp/omdp/pdf/GuidelinesforSubmissions.pdf>.